Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.

CONCLUSION: TKI was safely discontinued in clinical practice and yielded TFR rates similar to those observed in previous clinical trials, regardless of reason. Achievement of TFR significantly impacts patients' quality of life and should be considered in clinical practice. PMID: 30880635 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research